A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Head and Neck Neoplasms
  • Induction Chemotherapy

abstract

  • The phase 2 recommended dose was 7.5 mg daily for everolimus plus cisplatin and docetaxel (both at 75 mg/m(2) on day 1 of a 21-day cycle) given with pegfilgrastim support.

publication date

  • May 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3969235

Digital Object Identifier (DOI)

  • 10.1002/cncr.27986

PubMed ID

  • 23408298

Additional Document Info

start page

  • 1823

end page

  • 31

volume

  • 119

number

  • 10